IMMP Stock Price, Chart, Stats & News
Immutep Limited (IMMP) does not currently pay a dividend.
IMMP chart
Fundamentals
Gross margin | -943.86% |
Operating margin | -1523.47% |
Pretax margin | -1059.19% |
Net margin | -1059.19% |
Effective tax rate | – |
ROA | -57.01% |
ROE | -69.20% |
D/E | 0.01x |
Interest coverage ratio | -6372.76x |
IMMP valuation
P/E | – |
P/S | 9.53x |
P/B | 0.76x |
P/CF | -1.22x |
P/FCF | -1.22x |
P/OCF | -1.22x |
PEG | 0.02x |
EV multiple | -1.81x |
About
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
Similar securities
Based on sector and market capitalization
